CIPLA STRENGTHENS US PORTFOLIO WITH THE LAUNCH OF GENERIC SAXENDA® (LIRAGLUTIDE INJECTION) FOR WEIGHT MANAGEMENT THERAPY
CIPLA: TO LAUNCH GENERIC SAXENDA ON AN IMMEDIATE BASIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.